Prognostic Factors of the Clinical Response to Subcutaneous Immunotherapy with lnterleukin-2 Alone in Patients with Metastatic Renal Cell Carcinoma

Oncology ◽  
1994 ◽  
Vol 51 (1) ◽  
pp. 59-62 ◽  
Author(s):  
P. Lissoni ◽  
S. Barni ◽  
A. Ardizzoia ◽  
S. Crispino ◽  
F. Paolorossi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Subcutaneous Immunotherapy

scholarly journals PROGNOSTIC FACTORS IN PATIENTS WITH NON-METASTATIC RENAL CELL CARCINOMA

1996 ◽  
Vol 87 (9) ◽  
pp. 1099-1104
Author(s):  
Hideshi Inomiya ◽  
Shigeo Isaka ◽  
Tatsuya Okano ◽  
Jun Shimazaki ◽  
Tatsuo Igarashi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients

Urology ◽  
2013 ◽  
Vol 82 (4) ◽  
pp. 846-851 ◽  
Author(s):  
Sei Naito ◽  
Hidefumi Kinoshita ◽  
Tsunenori Kondo ◽  
Nobuo Shinohara ◽  
Takashi Kasahara ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Multicenter Study ◽  
Renal Cell

scholarly journals Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

2019 ◽  
Vol 2 (5) ◽  
pp. 269-271
Author(s):  
Keita Izumi ◽  
Yasumasa Iimura ◽  
Kiyoshi Hiruma ◽  
Tsuguhiro Touma ◽  
Tetsuro Tsukamoto
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Possible Correlation between Some Biologic Effects and the Clinical Course in Patiens Treated with Continuous Infusion of Interleukin-2 plus Alpha-2 Interferon for Metastatic Renal Cell Carcinoma

1994 ◽  
Vol 80 (5) ◽  
pp. 348-352 ◽  
Author(s):  
Claudia Baiocchi ◽  
Giuseppe Landonio ◽  
Gabriella Balzarmi ◽  
Carlo Cacioppo ◽  
Mario Calgaro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Complete Response ◽  
Antithyroid Antibodies ◽  
Biologic Effects

Background Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response. Methods Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte. Results Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33%) and 3 stable disease (20%): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a “score” system, was also related to a better clinical response. Conclusions Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document